title: An immunologic portrait of cancer.
abstract: The advent of high-throughput technology challenges the traditional histopathological classification of cancer, and proposes new taxonomies derived from global transcriptional patterns. Although most of these molecular re-classifications did not endure the test of time, they provided bulk of new information that can reframe our understanding of human cancer biology. Here, we focus on an immunologic interpretation of cancer that segregates oncogenic processes independent from their tissue derivation into at least two categories of which one bears the footprints of immune activation. Several observations describe a cancer phenotype where the expression of interferon stimulated genes and immune effector mechanisms reflect patterns commonly observed during the inflammatory response against pathogens, which leads to elimination of infected cells. As these signatures are observed in growing cancers, they are not sufficient to entirely clear the organism of neoplastic cells but they sustain, as in chronic infections, a self-perpetuating inflammatory process. Yet, several studies determined an association between this inflammatory status and a favorable natural history of the disease or a better responsiveness to cancer immune therapy. Moreover, these signatures overlap with those observed during immune-mediated cancer rejection and, more broadly, immune-mediated tissue-specific destruction in other immune pathologies. Thus, a discussion concerning this cancer phenotype is warranted as it remains unknown why it occurs in immune competent hosts. It also remains uncertain whether a genetically determined response of the host to its own cancer, the genetic makeup of the neoplastic process or a combination of both drives the inflammatory process. Here we reflect on commonalities and discrepancies among studies and on the genetic or somatic conditions that may cause this schism in cancer behavior.
authors.affiliation: Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Maria Libera
authors.initials: ML
authors.lastname: Ascierto
authors.forename: Valeria
authors.initials: V
authors.lastname: De Giorgi
authors.forename: Qiuzhen
authors.initials: Q
authors.lastname: Liu
authors.forename: Davide
authors.initials: D
authors.lastname: Bedognetti
authors.forename: Tara L
authors.initials: TL
authors.lastname: Spivey
authors.forename: Daniela
authors.initials: D
authors.lastname: Murtas
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Uccellini
authors.forename: Ben D
authors.initials: BD
authors.lastname: Ayotte
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: Lotfi
authors.initials: L
authors.lastname: Chouchane
authors.forename: Masoud H
authors.initials: MH
authors.lastname: Manjili
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D006801:Humans; D007109:Immunity / Q000276:immunology; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000276:immunology*; D011379:Prognosis; D059016:Tumor Microenvironment / Q000276:immunology